Thromb Haemost 2006; 95(05): 755
Schattauer GmbH
Antithrombin for severe sepsis? Try it again, but without heparin!
Bernd Jilma
1
Department of Clinical Pharmacology, Medical University of Vienna, Austria and Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, Florida, USA
› Author Affiliations
References
1
Kaneider NC,
Forster E,
Mosheimer B.
et al. Syndecan-4-dependent signaling in the inhibition of endotoxin-induced endothelial adherence of neutrophils by antithrombin. Thromb Haemost 2003; 90: 1150-7.
2
Leitner JM,
Firbas C,
Mayr FB.
et al. Recombinant human antithrombin inhibits thrombin formation and interleukin6 release in human endotoxemia. Clin Pharmacol Ther 2006; 79: 23-34.
3
Oelschlager C,
Römisch J,
Staubitz A.
et al. Antithrombin III inhibits nuclear factor kappaB activation in human monocytes and vascular endothelial cells. Blood 2002; 99: 4015-20.
4
Hoffmann JN,
Vollmar B,
Laschke MW.
et al. Adverse effect of heparin on antithrombin action during endotoxemia: microhemodynamic and cellular mechanisms. Thromb Haemost 2002; 88: 242-52.
5
Pulletz S,
Lehmann C,
Volk T.
et al. Influence of heparin and hirudin on endothelial binding of antithrombin in experimental thrombinemia. Crit Care Med 2000; 28: 2881-6.
6
Opal SM,
Kessler CM,
Roemisch J,
Knaub S.
Antithrombin, heparin, and heparan sulfate. Crit Care Med 2002; 30: 325-31.
7
Hoffmann JN,
Wiedermann CJ,
Juers M.
et al. Benefit/risk profile of high dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thromb Haemost 2006; 95: 850-6.
8
Wiedermann CJ,
Hoffmann JN,
Juers M.
et al. High-dose antithrombin III in the treatment of severe sepsis in patients witha high risk of death: efficacy and safety. Crit Care Med 2006; 34: 285-92.
9
Spiel AO,
Firbas C,
Mayr FB.
et al. The effects of supra-normal protein C levels on markers of coagulation, fibrinolysis and inflammation in a human model of endotoxemia. Thromb Haemost 2005; 94: 1148-55.
10
Derhaschnig U,
Reiter R,
Knobl P.
et al. Recombinant human activated proteinC (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia. Blood 2003; 102: 2093-8.
